Partner With Us
We believe in courageous innovation, which means taking on challenging medical conditions, finding solutions to complex problems, and never being afraid to partner with likeminded individuals, organizations, and companies who are committed to changing the world through biotechnology innovation.
Ocugen is dedicated to bringing our game-changing gene and cell therapy platforms to market to help patients who have diseases and conditions with limited or no treatment options. We are also developing an inhaled vaccine platform to address serious existing and future respiratory threats.
We are always open to collaborating with innovators and interested parties to advance our technologies around the world. If you are interested in working with Ocugen in any of our therapeutic areas:
bd@ocugen.com
Areas of Interest
Modifier Gene Therapy Platform
First-in-Class
- Therapeutic Focus: Inherited retinal diseases & larger blindness diseases with unmet need
- Differentiator: Master gene regulator; gene-agnostic approach
- Pipeline:
- OCU400 (Ph3) Broad retinitis pigementosa (RP) & (Ph1/2) Leber congenital amaurosis (LCA)
- OCU410 (Ph1/2): Dry AMD (geographic atrophy)
- OCU410ST (Ph1/2): Stargardt disease; orphan drug designation from FDA
Regenerative Cell Therapy Platform
First-in-Class
- Therapeutic Focus: Articular cartilage lesions
- Differentiator: 3-D scaffold
- Pipeline:
- NeoCart® (Ph3): Articular cartilage defects in the knee
- Ph3-ready
- cGMP manufacturing facility construction completed
- RMAT designation from FDA
- NeoCart® (Ph3): Articular cartilage defects in the knee
Inhalation Vaccines Platform
First-in-Class
- Therapeutic Focus: Flu and COVID-19
- Differentiator: Inhalation for improved durability and transmission control
- Pipeline:
- OCU500 (Preclin): COVID-19 vaccine (NIH/NIAID Nextgen Collaboration)
- OCU510 (Preclin): Flu quadrivalent
- OCU520 (Preclin): COVID-19 + flu combo
Why Partner with Ocugen
We are Pioneers
Ocugen is developing the world’s first modifier gene therapy platform. The initial applications are ophthalmic, but we aspire to treating many more conditions beyond the eye.
We have already identified several neurological conditions which are targets for our next wave of modifier gene therapies.
If you are interested in partnering with us on our revolutionary gene therapy platform – contact us now.
We are Innovators
Regenerative cell therapy holds immense promise to utilize the body’s own cells to heal diseases, conditions, and injuries.
We are leading the way in articular cartilage defect repair with our novel, proprietary bioreactor technology that enables cell differentiation and reimplantation of living tissue. Our unique 3D scaffold ensures lesions have the best environment for rapid recovery.
If you would like to know more about our regenerative cell therapy, reach out now.
We do things differently
Ocugen does not have a “follow the herd mentality.” We look at complex conditions and look beyond solutions others are trying. When the COVID-19 pandemic became a worldwide public health calamity, we identified a new way of addressing global respiratory threats – go to the source, protect the lungs and generate strong and durable immunity. To succeed we needed to partner – first to identify the very best vector then to scale the best delivery mechanism. The result is the world’s first inhaled vaccine platform.
Interested in helping us eradicate respiratory threats through a new approach to vaccinations? We’d love to hear from you.
We are vertically integrated
We don’t just discover and develop new first-in-class therapies, we can make them in our state-of-the-art manufacturing facility in Malvern, PA. We are completing facilities capable of domestic supply of our gene & cell therapy and vaccine technologies, and we have big plans to scale-up so we can supply the world.
But we can’t get there alone. Want to work with us to expand capabilities? – Just send us an email.